Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- Check6 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2; the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check13 days agoChange DetectedA notice about NIH websites transitioning from the term “Artificial Intelligence” to “Super Intelligence” appears above the study record page, which still displays a 403 error.SummaryDifference1%

- Check20 days agoChange DetectedThe site footer revision identifier changed from v3.7.1 to v3.7.2; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check48 days agoChange DetectedA 403 Forbidden error page is now displayed, replacing the study content and navigation with an error message and a Home link.SummaryDifference19%

- Check55 days agoChange DetectedThe page now adds 'Type 2 diabetes' under related topics and includes a MedlinePlus Genetics entry in related topics. These additions provide quick access to broader background information about the condition and genetics related to the study area.SummaryDifference0.2%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.